Skip to content

RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-Lock, Corail and Deltamotion Hip Replacement Components

RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-lock, Corail and Deltamotion Hip Replacement Components: a Single-blinded Randomised Control Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02696395
Acronym
DePuy RSA RCT
Enrollment
40
Registered
2016-03-02
Start date
2015-07-31
Completion date
2019-12-31
Last updated
2016-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

Hip replacements are being performed on an increasingly active population, who are likely to wear their implants out prematurely. New hip replacements have been devised to minimise the risk of failure. DePuy RSA RCT is a randomised controlled trial designed to compare the performance of two established types of hip replacements using Corail and Tri-Lock stems along with Deltamotion acetabular component. The primary objective of the trial is to compare the long term stability of these two devices.To do this, the study will use an advanced 3D Xray technique to detect migration of the components at 3 years. The study will also measure micromotion of Corail, Tri-Lock and Deltamotion components, patient reported outcome measures and change in bone density.This study is being conducted at a single site, at the Nuffield Orthopaedic Centre, Oxford.

Interventions

DEVICEDePuy Tri-Lock® femoral stem + Deltamotion® acetabular component
DEVICEDePuy Corail® femoral stem + Deltamotion® acetabular component

Sponsors

DePuy International
CollaboratorINDUSTRY
University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Women aged between 18 and 65 years and men aged between 18 and 70 years. * Participant is willing and able to give informed consent for participation in the study. * Diagnosed with hip osteoarthritis. * Able (in the Investigators opinion) and willing to comply with all study requirements. * Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion criteria

* Any patients with an inflammatory arthropathy, osteoporosis or deformities of the proximal femur. * Patients who have significant co-morbidities that would make follow-up difficult or uncomfortable. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Design outcomes

Primary

MeasureTime frame
Mean total Radio Stereometric Analysis (RSA) measured migration of DePuy Tri-Lock® femoral stem vs DePuy Corail® femoral stem (mm/yr).3 years

Secondary

MeasureTime frame
Dynamically Inducible Micromotion (DIMM) of DePuy Corail®, Tri-Lock® and Deltamotion® components (mm/yr).3 years
Radio Stereometric Analysis (RSA) measured migration of DePuy Deltamotion® acetabular component3 years
Change in Oxford Hip Score (OHS) at three years.3 years
Change in bone density using Dual Energy X-Ray Absorptiometry (DEXA) scan at 12 months.1 year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026